Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Endothelial Disfunction Treatment With Glimepiride/Metformin Combination (Glimetal) in Type 2 Diabetes Patients

This study has been completed.
Information provided by (Responsible Party):
Laboratorios Silanes S.A. de C.V. Identifier:
First received: September 5, 2011
Last updated: September 6, 2011
Last verified: September 2011
The Purpose of this study was to evaluate the effect of the combination glimepiride/metformin over endothelial dysfunction (ED) in asymptomatic patients with type 2 diabetes mellitus (DM) using 13N-ammonia-positron emission tomography (PET).

Condition Intervention Phase
Endothelial Dysfunction
Diabetes Mellitus
Drug: Glimepiride/metformin
Drug: Metformin
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Endothelial Disfunction Treatment With Glimepiride/Metformin Combination (Glimetal) in Type 2 Diabetes Patients. Positron Emission Tomography Assessment(PET)

Resource links provided by NLM:

Further study details as provided by Laboratorios Silanes S.A. de C.V.:

Primary Outcome Measures:
  • EDVI [ Time Frame: 8 weeks ]
    endothelial-dependent vasodilation index

  • MFR [ Time Frame: 8 weeks ]
    myocardial flow reserve

  • %ΔMBF [ Time Frame: 8 weeks ]
    percentage of the change between rest and CPT

Secondary Outcome Measures:
  • Fasting glucose [ Time Frame: 8 weeks ]
  • Glycated hemoglobin [ Time Frame: 8 weeks ]
  • Adverse effects [ Time Frame: 8 weeks ]

Enrollment: 16
Study Start Date: July 2007
Study Completion Date: January 2008
Primary Completion Date: January 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Glimepiride/metformin Drug: Glimepiride/metformin
4/1000 mg tablets once a day foe eight weeks
Other Name: GLIMETAL
Active Comparator: Metformin Drug: Metformin
1000 mg tablets once daily for eight weeks
Other Name: PREDIAL


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Both genders
  • At least 18 years old
  • Type 2 diabetes mellitus diagnosis
  • Signed Informed Consent

Exclusion Criteria:

  • History of smoking, hypertension, dyslipidemia, ischemic heart disease or autoimmune rheumatic diseases
  • Pregnancy or lactation
  • History of abuse and/or substance dependence within 6 months preceding the survey.
  • History of glimepiride or metformin allergy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01429818

Unidad PET Ciclotrón. Facultad de Medicina. Universidad Nacional Autónoma de México
Mexico city, Distrito Federal, Mexico, 04510
Sponsors and Collaborators
Laboratorios Silanes S.A. de C.V.
Study Director: Jorge González, MD Laboratorios Silanes S.A. de C.V.
  More Information

Responsible Party: Laboratorios Silanes S.A. de C.V. Identifier: NCT01429818     History of Changes
Other Study ID Numbers: PET-GLI01
Study First Received: September 5, 2011
Last Updated: September 6, 2011

Keywords provided by Laboratorios Silanes S.A. de C.V.:
Endothelial dysfunction
Diabetes mellitus

Additional relevant MeSH terms:
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Hypoglycemic Agents
Physiological Effects of Drugs
Anti-Arrhythmia Agents
Immunosuppressive Agents
Immunologic Factors processed this record on April 27, 2017